;PMID: 2437946
;source_file_2838.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..36] = [t:0..36]
;1)sentence:[e:42..128] = [t:42..128]
;2)section:[e:132..260] = [t:132..260]
;3)sentence:[e:264..432] = [t:264..432]
;4)sentence:[e:433..600] = [t:433..600]
;5)sentence:[e:601..693] = [t:601..693]
;6)sentence:[e:694..809] = [t:694..809]
;7)sentence:[e:810..900] = [t:810..900]
;8)sentence:[e:901..1006] = [t:901..1006]
;9)sentence:[e:1007..1146] = [t:1007..1146]
;10)sentence:[e:1147..1268] = [t:1147..1268]
;11)section:[e:1272..1316] = [t:1272..1316]

;section 0 Span:0..36
;Br J Cancer.  1987 Apr;55(4):407-11.
(SEC
  (FRAG (NNP:[0..2] Br) (NNP:[3..4] J) (NNP:[5..11] Cancer) (.:[11..12] .)
        (CD:[14..18] 1987) (NNP:[19..22] Apr) (::[22..23] ;) (CD:[23..25] 55)
        (-LRB-:[25..26] -LRB-) (CD:[26..27] 4) (-RRB-:[27..28] -RRB-)
        (::[28..29] :) (CD:[29..35] 407-11) (.:[35..36] .)))

;sentence 1 Span:42..128
;Biological properties of a tumour cell line (NB1-G) derived from human 
;neuroblastoma.
;[114..127]:malignancy-type:"neuroblastoma"
(SENT
  (NP-HLN
    (NP (JJ:[42..52] Biological) (NNS:[53..63] properties))
    (PP (IN:[64..66] of)
      (NP
        (NP
          (NP (DT:[67..68] a) (NN:[69..75] tumour) (NN:[76..80] cell)
              (NN:[81..85] line))
          (NP (-LRB-:[86..87] -LRB-) (NN:[87..92] NB1-G) (-RRB-:[92..93] -RRB-)))
        (VP (VBN:[94..101] derived)
          (NP (-NONE-:[101..101] *))
          (PP (IN:[102..106] from)
            (NP (JJ:[107..112] human) (NN:[114..127] neuroblastoma))))))
    (.:[127..128] .)))

;section 2 Span:132..260
;Carachi R, Raza T, Robertson D, Wheldon TW, Wilson L, Livingstone A, van 
;Heyningen V, Spowart G, Middleton P, Gosden JR, et al.
(SEC
  (FRAG (NNP:[132..139] Carachi) (NNP:[140..141] R) (,:[141..142] ,)
        (NNP:[143..147] Raza) (NNP:[148..149] T) (,:[149..150] ,)
        (NNP:[151..160] Robertson) (NNP:[161..162] D) (,:[162..163] ,)
        (NNP:[164..171] Wheldon) (NNP:[172..174] TW) (,:[174..175] ,)
        (NNP:[176..182] Wilson) (NNP:[183..184] L) (,:[184..185] ,)
        (NNP:[186..197] Livingstone) (NNP:[198..199] A) (,:[199..200] ,)
        (NNP:[201..204] van) (NNP:[206..215] Heyningen) (NNP:[216..217] V)
        (,:[217..218] ,) (NNP:[219..226] Spowart) (NNP:[227..228] G)
        (,:[228..229] ,) (NNP:[230..239] Middleton) (NNP:[240..241] P)
        (,:[241..242] ,) (NNP:[243..249] Gosden) (NNP:[250..252] JR)
        (,:[252..253] ,) (NNP:[254..256] et) (FW:[257..259] al) (.:[259..260] .)))

;sentence 3 Span:264..432
;The properties of a new tumour cell line (NB1-G) derived from human 
;neuroblastoma by xenografting in nude rats followed by adaptation to tissue 
;culture are described.
;[333..346]:malignancy-type:"neuroblastoma"
(SENT
  (S
    (NP-SBJ-1
      (NP (DT:[264..267] The) (NNS:[268..278] properties))
      (PP (IN:[279..281] of)
        (NP
          (NP
            (NP (DT:[282..283] a) (JJ:[284..287] new) (NN:[288..294] tumour)
                (NN:[295..299] cell) (NN:[300..304] line))
            (NP (-LRB-:[305..306] -LRB-) (NN:[306..311] NB1-G)
                (-RRB-:[311..312] -RRB-)))
          (VP (VBN:[313..320] derived)
            (NP (-NONE-:[320..320] *))
            (PP (IN:[321..325] from)
              (NP (JJ:[326..331] human) (NN:[333..346] neuroblastoma)))
            (PP-MNR (IN:[347..349] by)
              (NP
                (NP
                  (NP (NN:[350..362] xenografting))
                  (PP-LOC (IN:[363..365] in)
                    (NP (JJ:[366..370] nude) (NNS:[371..375] rats))))
                (VP (VBN:[376..384] followed)
                  (NP (-NONE-:[384..384] *))
                  (PP (IN:[385..387] by)
                    (NP-LGS
                      (NP (NN:[388..398] adaptation))
                      (PP (TO:[399..401] to)
                        (NP
                          (NML (NN:[402..408] tissue) (NN:[410..417] culture)))))))))))))
    (VP (VBP:[418..421] are)
      (VP (VBN:[422..431] described)
        (NP-1 (-NONE-:[431..431] *))))
    (.:[431..432] .)))

;sentence 4 Span:433..600
;Studies using a panel of monoclonal antibodies  demonstrate the
;neuro-ectodermal nature of the cells and support the diagnosis  of the
;primary tumour as neuroblastoma.
;[458..479]:gene-protein:"monoclonal antibodies"
;[568..575]:malignancy-clinical-stage:"primary"
;[576..582]:malignancy-type:"tumour"
;[586..599]:malignancy-type:"neuroblastoma"
(SENT
  (S
    (NP-SBJ
      (NP (NNS:[433..440] Studies))
      (VP (VBG:[441..446] using)
        (NP
          (NP (DT:[447..448] a) (NN:[449..454] panel))
          (PP (IN:[455..457] of)
            (NP (JJ:[458..468] monoclonal) (NNS:[469..479] antibodies))))))
    (VP
      (VP (VBP:[481..492] demonstrate)
        (NP
          (NP (DT:[493..496] the)
            (ADJP (AFX:[497..502] neuro) (HYPH:[502..503] -)
                  (JJ:[503..513] ectodermal))
            (NN:[514..520] nature))
          (PP (IN:[521..523] of)
            (NP (DT:[524..527] the) (NNS:[528..533] cells)))))
      (CC:[534..537] and)
      (VP (VBP:[538..545] support)
        (NP
          (NP (DT:[546..549] the) (NN:[550..559] diagnosis))
          (PP (IN:[561..563] of)
            (NP (DT:[564..567] the) (JJ:[568..575] primary)
                (NN:[576..582] tumour)))
          (PP (IN:[583..585] as)
            (NP (NN:[586..599] neuroblastoma))))))
    (.:[599..600] .)))

;sentence 5 Span:601..693
;Cytogenetic studies have revealed a  human karyotype with several chromosomal
;abnormalities.
(SENT
  (S
    (NP-SBJ (JJ:[601..612] Cytogenetic) (NNS:[613..620] studies))
    (VP (VBP:[621..625] have)
      (VP (VBN:[626..634] revealed)
        (NP
          (NP (DT:[635..636] a) (JJ:[638..643] human) (NN:[644..653] karyotype))
          (PP (IN:[654..658] with)
            (NP (JJ:[659..666] several) (JJ:[667..678] chromosomal)
                (NNS:[679..692] abnormalities))))))
    (.:[692..693] .)))

;sentence 6 Span:694..809
;Genetic analysis by in  situ DNA hybridization has demonstrated the presence
;of multiple copies of the  N-myc gene.
;[798..803]:gene-rna:"N-myc"
(SENT
  (S
    (NP-SBJ
      (NP (JJ:[694..701] Genetic) (NN:[702..710] analysis))
      (PP (IN:[711..713] by)
        (NP
          (ADJP (FW:[714..716] in) (FW:[718..722] situ))
          (NN:[723..726] DNA) (NN:[727..740] hybridization))))
    (VP (VBZ:[741..744] has)
      (VP (VBN:[745..757] demonstrated)
        (NP
          (NP (DT:[758..761] the) (NN:[762..770] presence))
          (PP (IN:[771..773] of)
            (NP
              (NP (JJ:[774..782] multiple) (NNS:[783..789] copies))
              (PP (IN:[790..792] of)
                (NP (DT:[793..796] the) (NN:[798..803] N-myc)
                    (NN:[804..808] gene))))))))
    (.:[808..809] .)))

;sentence 7 Span:810..900
;Approximately 20-30 fold amplification of the gene is observed on  Southern
;blot analysis.
;[835..848]:variation-type:"amplification"
;[852..860]:gene-rna:"the gene"
(SENT
  (S
    (NP-SBJ-1
      (NP
        (QP (RB:[810..823] Approximately) (CD:[824..826] 20) (HYPH:[826..827] -)
            (CD:[827..829] 30) (JJ:[830..834] fold))
        (NN:[835..848] amplification))
      (PP (IN:[849..851] of)
        (NP (DT:[852..855] the) (NN:[856..860] gene))))
    (VP (VBZ:[861..863] is)
      (VP (VBN:[864..872] observed)
        (NP-1 (-NONE-:[872..872] *))
        (PP (IN:[873..875] on)
          (NP
            (NML (JJ:[877..885] Southern) (NN:[886..890] blot))
            (NN:[891..899] analysis)))))
    (.:[899..900] .)))

;sentence 8 Span:901..1006
;The cell line has been adapted to growth as  multicellular tumour spheroids
;as well as monolayer culture.
(SENT
  (S
    (NP-SBJ-1 (DT:[901..904] The) (NN:[905..909] cell) (NN:[910..914] line))
    (VP (VBZ:[915..918] has)
      (VP (VBN:[919..923] been)
        (VP (VBN:[924..931] adapted)
          (NP-1 (-NONE-:[931..931] *))
          (PP (TO:[932..934] to)
            (NP
              (NP (NN:[935..941] growth))
              (PP (IN:[942..944] as)
                (NP
                  (NP (JJ:[946..959] multicellular) (NN:[960..966] tumour)
                      (NNS:[967..976] spheroids))
                  (CONJP (RB:[977..979] as) (RB:[980..984] well)
                         (IN:[985..987] as))
                  (NP (NN:[988..997] monolayer) (NN:[998..1005] culture)))))))))
    (.:[1005..1006] .)))

;sentence 9 Span:1007..1146
;Radiobiological  studies on spheroids show the cells to be radiosensitive
;with low capacity for  sub-lethal damage accumulation and repair.
(SENT
  (S
    (NP-SBJ
      (NP (JJ:[1007..1022] Radiobiological) (NNS:[1024..1031] studies))
      (PP (IN:[1032..1034] on)
        (NP (NNS:[1035..1044] spheroids))))
    (VP (VBP:[1045..1049] show)
      (S
        (NP-SBJ (DT:[1050..1053] the) (NNS:[1054..1059] cells))
        (VP (TO:[1060..1062] to)
          (VP (VB:[1063..1065] be)
            (ADJP-PRD (JJ:[1066..1080] radiosensitive))
            (PP (IN:[1081..1085] with)
              (NP
                (NP (JJ:[1086..1089] low) (NN:[1090..1098] capacity))
                (PP (IN:[1099..1102] for)
                  (NP
                    (NP
                      (NML-1
                        (ADJP (AFX:[1104..1107] sub) (HYPH:[1107..1108] -)
                              (JJ:[1108..1114] lethal))
                        (NN:[1115..1121] damage))
                      (NN:[1122..1134] accumulation))
                    (CC:[1135..1138] and)
                    (NP
                      (NML-1 (-NONE-:[1138..1138] *P*))
                      (NN:[1139..1145] repair))))))))))
    (.:[1145..1146] .)))

;sentence 10 Span:1147..1268
;The cell line should be useful for  fundamental studies of human
;neuroblastoma as well as experimental therapy in  vitro.
;[1212..1225]:malignancy-type:"neuroblastoma"
(SENT
  (S
    (NP-SBJ (DT:[1147..1150] The) (NN:[1151..1155] cell) (NN:[1156..1160] line))
    (VP (MD:[1161..1167] should)
      (VP (VB:[1168..1170] be)
        (ADJP-PRD (JJ:[1171..1177] useful))
        (PP (IN:[1178..1181] for)
          (NP
            (NP (JJ:[1183..1194] fundamental) (NNS:[1195..1202] studies))
            (PP (IN:[1203..1205] of)
              (NP
                (NP
                  (NP (JJ:[1206..1211] human) (NN:[1212..1225] neuroblastoma))
                  (CONJP (RB:[1226..1228] as) (RB:[1229..1233] well)
                         (IN:[1234..1236] as))
                  (NP (JJ:[1237..1249] experimental) (NN:[1250..1257] therapy)))
                (ADVP (FW:[1258..1260] in) (FW:[1262..1267] vitro))))))))
    (.:[1267..1268] .)))

;section 11 Span:1272..1316
;PMID: 2437946 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1272..1276] PMID) (::[1276..1277] :) (CD:[1278..1285] 2437946)
        (NN:[1286..1287] -LSB-) (NNP:[1287..1293] PubMed) (::[1294..1295] -)
        (NN:[1296..1303] indexed) (IN:[1304..1307] for)
        (NNP:[1308..1315] MEDLINE) (-RRB-:[1315..1316] -RSB-)))
